At Surface Oncology, we are investigating next generation immunotherapies to treat a wide range of cancers.
Clinical trials are an essential part of the drug development process and help ensure that new therapies are safe and effective.
We are tremendously grateful to the patient volunteers who participate in our studies and the clinical investigators who work with us in our mission to improve human health.
Information about our clinical trials can be found on www.clinicaltrials.gov:
- A Phase 1 Study of SRF617 in Patients With Advanced Solid Tumors NCT04336098
- A Phase 2 Trial of SRF617 in Combination With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration-Resistant Prostate Cancer NCT05177770
- A Phase 1/1b Study of SRF388 in Patients With Advanced Solid Tumors NCT04374877
- A Randomized Phase 2 Trial of Atezolizumab and Bevacizumab in Combination With SRF388 or Placebo in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma NCT05359861
For more information about SRF388, SRF617, the types of cancers being studied in our clinical trials, or published data, please see our Pipeline.